A structural map of KRAS(G12C), showing the AMG 510 molecule in the binding pocket. Amgen is a Participating Research Team member of the Berkeley Center for Structural Biology (BCSB), which maintains and operates five of the ALS beamlines. (Credit: Amgen)
An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies.
The drug, developed by Amgen and currently referred to as AMG 510, is the first therapy to reach clinical trials that inhibits a mutant KRAS protein. Errors in the KRAS gene, which encodes a crucial cell signaling protein, are one of the most common causes of cancer.
The particular mutant inhibited by AMG 510 – called KRAS(G12C) – is present in approximately 13% of lung adenocarcinomas, 3% of colorectal cancers, and 2% of other solid tumors.
Despite its significant role in the pathogenesis of cancer, scientists have been unable to design KRAS-specific therapeutics due to the shape of the protein – it has an exceptionally smooth surface with no obvious regions for a drug molecule to bind. Seeking to develop a long-sought direct inhibitor, researchers at Amgen conducted X-ray crystallography of KRAS(G12C) proteins at Berkeley Lab’s Advanced Light Source (ALS). The high-resolution structural maps generated using the data acquired at the beamlines helped Amgen make the breakthrough discovery of a small pocket on the molecule. In subsequent studies, the beamline data allowed scientists to investigate atomic-level molecular interactions between KRAS(G12C) and potential inhibiting compounds that bind in this pocket. AMG 510 emerged as a very promising candidate after a multiyear drug agent optimization program.
“It’s rare that a compound gets all the way through the development process and becomes a drug. So, for the BCSB team, it feels great to see our (small) contribution finding its way to fight diseases,” said Marc Allaire, one of the Berkeley Lab biophysicists who operate the BCSB beamlines.
Learn more: Unique Cancer Drug Discovered With Help From Advanced Light Source Begins Historical Clinical Trial
Go deeper with Bing News on:
Investigational cancer drug
- Tetra Announces Positive Initial Data From Phase 2 Trials Of QIXLEEF For Cancer Pain
Tetra Bio-Pharma Inc. (TBPMF, TBP.TO) announced positive initial clinical data from its ongoing Phase 2 clinical trials--REBORN1 and ...
- Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Based on these and other preclinical data, Lengo Therapeutics anticipates it will submit an investigational new drug (IND) application for LNG-451 ... treatment for patients with EGFR-driven lung ...
- Avacta Group plc: Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
Enables expansion of recruitment into ongoing phase I study to include eligible US patients upon opening of clinical sites in early 2022 Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutica ...
- Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is ...
- Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients ...
Go deeper with Google Headlines on:
Investigational cancer drug
Go deeper with Bing News on:
Cancer drug
- Science Writing Prize 2021 – Personal source code: leveraging personal proteogenomics for targeted cancer therapy
Dr James Wright covers the evolving field of proteogenomics and its future for targeted cancer therapies in this piece shortlisted for the 2021 Mel Greaves Science Writing Prize.
- Science Writing Prize 2021 – The next big thing: diving into the ‘immunoverse’ to create novel and personalised cancer therapies
Dr Vivian Dimou explores the 'immunoverse' – the interplay between immune cells and their surrounding tissue environment – in this piece shortlisted for the 2021 Mel Greaves Science Writing Prize.
- Tetra Announces Positive Initial Data From Phase 2 Trials Of QIXLEEF For Cancer Pain
Tetra Bio-Pharma Inc. (TBPMF, TBP.TO) announced positive initial clinical data from its ongoing Phase 2 clinical trials--REBORN1 and ...
- HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting regulatory sites on proteins referred to as "natural ...
- Microneedle Drug Delivery Systems Market is poised to reach US$1.2 Billion at a CAGR of 6.6% by 2020-2030
Emerging applications of microneedle drug delivery systems are expected to fuel their demand over the next decade. According to a recent report published by Future Market Insights (FMI), the global ...
